Furthermore, an ongoing clinical trial is studying the safety and efficacy of CAR-T cells targeting HER2 in subjects with progressive recurrent or refractory HER2-positive primary central nervous system (CNS) tumors or HER2-positive tumor metastatic to the CNS after standard intervention (NCT02442297). Here, ERBB2 is linked to neoplasm.